Anticancer agents: towards the future

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Chemotherapy faces challenges with non-specific drug action, leading to side effects.
• The development of targeted cancer therapies is a significant unmet need.
• Selective drug recognition offers a promising strategy to enhance therapeutic efficacy and reduce toxicity.

Purpose of the Study:

• To review recent advancements in selective drug recognition for cancer chemotherapy.
• To discuss the potential of targeting key molecules like tyrosine kinases, DNA-topoisomerases, and telomerase.
• To provide perspectives on future directions in the development of cancer cell-specific drugs.

Main Methods:

• Literature review of recent research in targeted cancer therapy.
• Analysis of drug recognition mechanisms for specific molecular targets.
• Discussion of emerging strategies in medicinal chemistry and drug design.

Main Results:

• Significant progress has been made in identifying and targeting key cancer-related molecules.
• Selective inhibitors for tyrosine kinases, DNA-topoisomerases, and telomerase show therapeutic promise.
• The field is advancing towards more precise and effective cancer treatments.

Conclusions:

• Selective drug recognition is a vital strategy for developing next-generation cancer chemotherapies.
• Targeting tyrosine kinases, DNA-topoisomerases, and telomerase offers distinct avenues for drug development.
• Continued research in this area is essential for improving patient outcomes in cancer treatment.